FOR HOSPITALS & HEALTH SYSTEMS

Your cardiac program's quality is documented whether you document it or not.

WhiteGloveMD gives your cardiac surgical program structured risk scoring, Heart Team documentation, and outcomes tracking — improving quality metrics, reducing liability, and retaining the cases you should be performing.

Request Enterprise Demo →(702) 553-0340

HIPAA compliant · SOC 2 Type II · HL7 FHIR integration · Epic & Cerner compatible

PLATFORM IMPACT SUMMARY
Care plans changed after independent review
Mayo Clinic Proceedings, 2017
66%
Average savings per redirected case
Industry data
$36K
Cost of one major surgical complication
CMS/hospital financial data
$300K+
Documentation with source-linked provenance
WhiteGloveMD platform
100%
Based on published literature and platform data
THE COST OF INACTION

What happens when cardiac decisions are undocumented.

Every unreviewed cardiac surgical case represents unquantified clinical risk, undocumented decision-making, and indefensible liability.

COST PER INCIDENT \u2014 CARDIAC SURGICAL ADVERSE EVENTS
Malpractice settlement
$500K – $2M+
Major complication (extended ICU)
$300K – $600K
30-day readmission (CMS penalty)
$150K – $300K
Lost case to competing hospital
$150K – $300K
WhiteGloveMD review (per case)
$250 – $500

One prevented complication pays for an entire year of platform access. One defended malpractice claim pays for a decade.

TWO FAILURE MODES

There are two ways your cardiac program loses without independent review.

Both are preventable. Both are expensive. Both are happening now at hospitals that believe their internal quality processes are sufficient.

INDEPENDENT REVIEW PERFORMED
YES
OPTIMAL

Patient received independent review. Surgery was appropriate. Outcome was good. Documentation is complete and defensible.

→ Quality documented. Liability minimal. Patient retained.

DEFENSIBLE

Patient received independent review. Surgery was indicated and appropriate per review. Outcome was nonetheless poor. Documentation proves the decision was evidence-based.

→ Decision defensible. Risk was quantified and accepted. Litigation exposure significantly reduced.

UNDOCUMENTED

Patient did NOT receive independent review. Surgery was performed. Outcome was good. But the decision-making process is undocumented — the hospital was lucky, not defensible.

→ Good outcome, no documentation. Quality metrics unaffected — but this time.

INDEFENSIBLE

Patient did NOT receive independent review. Outcome was poor. Discovery reveals: no structured risk scoring, no documented alternatives, no Heart Team conference record. A competing institution had better published outcomes for this procedure. The hospital's position is indefensible.

→ Malpractice exposure. Quality metrics degraded. Patient lost. Reputation damaged. Cost: $500K–$2M+.

NO
GOOD OUTCOMEPOOR OUTCOME
SURGICAL OUTCOME

WhiteGloveMD eliminates the bottom row. Every cardiac surgical case your hospital processes through the platform moves from undocumented or indefensible to optimal or defensible. The risk matrix shrinks.

THE PLATFORM

WhiteGloveMD integrates into your cardiac program.

Not a bolt-on. Not a referral service. A clinical decision support platform that becomes part of your cardiac surgical workflow — improving documentation, outcomes, and defensibility for every case.

Quality Improvement

Pre-surgical review identifies cases where risk is underestimated, alternatives exist, or surgeon-case matching can improve. Triple risk scoring (STS, EuroSCORE II, AATS) and guideline mapping create a quality baseline for every cardiac surgical case. STS star ratings improve when operative mortality and complications decrease.

Risk Reduction

Every reviewed case generates a documented clinical artifact — source-linked risk scoring, alternatives analysis, Heart Team recommendation, and physician co-signatures. In litigation, this documentation demonstrates evidence-based decision-making that hospital-only notes cannot match.

Case Retention

When WhiteGloveMD reviews a case within your hospital system, the patient stays in your system. Without it, patients who independently seek second opinions may be redirected to competing institutions. The platform keeps cases where they belong — at your hospital, with your surgeons.

All three operate simultaneously. A single platform investment produces quality, legal, and financial returns.

RETURN ON INVESTMENT

The math for a 500-case cardiac program.

A mid-size cardiac program performing 500 cases annually with WhiteGloveMD integration. Conservative assumptions.

500
Annual cardiac cases
Mid-size program
~65%
Plans refined or changed
Published second opinion data
$36K
Average savings per redirected case
Industry estimates
$250–$500
WhiteGloveMD cost per case
Enterprise pricing
20–50×
Potential ROI multiple
Against one complication avoided
ANNUAL COST COMPARISON \u2014 500-CASE PROGRAM
One surgical complication
$300K – $600K
One malpractice settlement
$500K – $2M
One CMS readmission penalty
$150K – $300K
Annual WhiteGloveMD enterprise
$125K – $250K

Annual platform cost is typically less than the cost of a single major complication. The question is not whether the hospital can afford WhiteGloveMD. The question is whether it can afford not to have it.

INTEGRATION ARCHITECTURE

How WhiteGloveMD integrates into hospital operations.

The platform touches six operational domains. Once integrated, it becomes part of the hospital's clinical infrastructure.

WhiteGloveMD
Platform
EMR INTEGRATION
HL7 FHIR. Review data flows into patient record automatically.
QUALITY REPORTING
STS metric tracking. Quarterly quality reviews. Benchmark comparison.
CREDENTIALING
Surgeon outcomes data supports privileging and peer review.
RISK MANAGEMENT
Documented decision-making. Pre-surgical evidence trail. Litigation defense.
PATIENT ACQUISITION
Employer channel. Direct consumer. Referring physician network.
BILLING & COMPLIANCE
Pre-authorization support. CMS compliance documentation. Audit readiness.

Once WhiteGloveMD is integrated into EMR workflows, quality reporting, and risk management processes, removing it requires rebuilding six operational dependencies simultaneously. The platform becomes infrastructure.

IMPLEMENTATION

From agreement to full integration in 90 days.

PHASE 1
PILOT
Weeks 1–4

10–25 cases reviewed. Platform deployed alongside existing workflow. No EMR integration required. Results measured against internal benchmarks.

→ Pilot outcomes report
PHASE 2
INTEGRATION
Weeks 4–8

EMR integration via HL7 FHIR. Quality reporting pipeline established. Credentialing committee receives surgeon outcomes data. Risk management receives case documentation.

→ Integration verification + first quarterly report
PHASE 3
FULL DEPLOYMENT
Weeks 8–12

All cardiac surgical cases processed through WhiteGloveMD. Quarterly quality reviews automated. Patient-facing channel active. Employer partnerships available. Outcomes tracking feeding STS benchmarks.

→ Full operational integration + ongoing quarterly reviews
NO UPFRONT TECHNOLOGY COST

WhiteGloveMD provides integration engineering at no additional cost. The platform fee covers EMR integration, training, and ongoing support.

DEDICATED IMPLEMENTATION TEAM

A clinical integration specialist and technical engineer are assigned to every hospital deployment.

COMPETITIVE LANDSCAPE

Where WhiteGloveMD sits in the hospital quality ecosystem.

CapabilityInternal Quality Programs
Peer review, M&M conference
Consulting Groups
Vizient, Press Ganey
Generalist Second Opinion
Accolade, Included Health
WhiteGloveMD Enterprise
Cardiac SpecializationYes — limited to staffGeneral — all specialtiesGeneral — all conditionsCardiac surgery exclusively
IndependenceInternal — inherent conflictExternal advisoryPlatform-employedFully independent
Validated Risk ScoringAd hoc, if anySTS + EuroSCORE II + AATS
Heart Team DocumentationInformal, variableMandatory, co-signed
Source-Linked ProvenanceEvery data point
EMR IntegrationNativeDashboardHL7 FHIR, Epic/Cerner
Outcomes TrackingSTS participationRetrospective analysisProspective registry
Patient-Facing ChannelConsumer platformConsumer + employer + hospital
Litigation DefenseVariable documentationRetrospective onlyPre-surgical evidence trail
Revenue GenerationEmployer + consumer channels

WhiteGloveMD is not a replacement for internal quality programs. It is the independent clinical intelligence layer that internal programs cannot provide — because independence requires being outside the institution.

EXECUTIVE PERSPECTIVE

What hospital leaders are asking.

“We spend millions on quality improvement programs that analyze outcomes after they happen. This is the first platform I’ve seen that intervenes before the outcome is determined — at the point of surgical decision-making.”

Chief Quality Officer800-bed academic medical center, evaluating WhiteGloveMD integration

“My concern was always: what happens when a patient gets a second opinion somewhere else and gets redirected to a competitor? With WhiteGloveMD integrated into our program, the second opinion happens inside our system. We keep the case and improve the documentation.”

VP of Cardiac ServicesMulti-hospital health system, 1,200+ cardiac cases annually
QUESTIONS

Frequently asked by hospital leadership.

Via HL7 FHIR API. We have validated integrations with Epic and Cerner. Review data — risk scores, Heart Team recommendation, source-linked report — flows into the patient record as a structured clinical document. Implementation typically takes 4–8 weeks with our dedicated integration engineering team.

No. WhiteGloveMD provides the reviewing physicians. The cardiac surgeon and interventional cardiologist who review cases are WhiteGloveMD physicians — independent of your hospital staff. Your surgeons and cardiologists receive the review output, not the review workload.

WhiteGloveMD’s pre-surgical review identifies cases where risk is underestimated, alternatives exist, or surgeon-case matching can be optimized. Over time, this should improve operative mortality and complication rates — the primary drivers of STS star ratings. We also provide quarterly quality reviews that benchmark your program’s WhiteGloveMD-reviewed cases against STS national averages.

Enterprise pricing is per-case with volume tiers. Typical range: $250–$500 per reviewed case depending on volume commitment. Annual platform cost for a 500-case program: approximately $125K–$250K. There is no upfront technology fee — integration engineering, training, and ongoing support are included.

Yes — and we recommend it. Phase 1 is a 4-week pilot processing 10–25 cases with no EMR integration required. The pilot produces a measurable outcomes report that your quality committee can evaluate before committing to full integration.

The opposite. WhiteGloveMD’s review is positioned as decision support, not oversight. Surgeons receive structured risk data and documented alternatives that strengthen their pre-operative planning. In approximately 35% of cases, the review confirms the surgical plan — giving the surgeon documented validation. In cases where the review identifies a concern, the surgeon has evidence-based data to refine the approach.

AES-256 encryption in transit and at rest. SOC 2 Type II compliant. Business Associate Agreement executed with every hospital partner. All data processing occurs in HIPAA-compliant infrastructure. Patient consent for independent review is integrated into the hospital’s existing consent workflow.

WhiteGloveMD’s employer partnerships generate direct patient referrals into your hospital’s cardiac program. Self-insured employers in your market offer WhiteGloveMD as an employee benefit — and those employees are routed to WhiteGloveMD-integrated hospitals for surgical care. This creates a new patient acquisition channel that your competitors do not have.

Your cardiac program's quality is either documented or it isn't.

Request a confidential demo. See the platform with your hospital's data profile.

Request Enterprise Demo →(702) 553-0340
enterprise@whiteglovemd.com
Clinical Rigor →·Outcomes & Evidence →·For Employers →